First Zantac cancer case dropped before trial, without settlement
The first lawsuit claiming that gastrointestinal drug Zantac causes cancer has been voluntarily dismissed a week before it was due to come to trial, in […]
The first lawsuit claiming that gastrointestinal drug Zantac causes cancer has been voluntarily dismissed a week before it was due to come to trial, in […]
Leading dermatologists discuss the innovations shaping 5 chronic skin diseases—psoriasis, atopic dermatitis, alopecia areata, vitiligo, and hidradenitis suppurativa—and share the challenges and opportunities for biopharmaceutical […]
On the same day as it reported encouraging new data for its cancer drug Trodelvy, Gilead Sciences has agreed a deal to buy rights to […]
The FDA has started a review of Roche’s Polivy for people with previously untreated diffuse large B-cell lymphoma (DLBCL), as the drugmaker tries to move […]
AstraZeneca and Merck & Co’s PARP inhibitor Lynparza is already used to treat prostate cancer associated with a specific genetic mutation, but could see its […]
Johnson & Johnson has said it will stop selling talc-based baby powder products globally next year, two years after halting sales in the US and […]
Half a million people in the UK with conditions like blood cancer that prevents them being protected from COVID-19 vaccines are facing another winter shielding, […]
GSK, its consumer health spin-off Haleon and Sanofi could be on the hook for billions of dollars in potential damages over Zantac, a gastrointestinal drug […]
Pfizer’s reported interest in acquiring sickle cell disease specialist Global Blood Therapeutics (GBT) has been confirmed, with the $68.50-per-share deal valuing GBT at $5.4 billion. […]
Bayer has won a key FDA approval to extend the use of its prostate cancer therapy Nubeqa, as it tries to claim market share from […]
Pfizer is on the brink of announcing a deal to buy Global Blood Therapeutics (GBT) and its oral therapy Oxbryta for sickle cell disease for […]
The largest pharma companies have all set themselves ambitious targets in recent years to improve representation for women and minority communities in their businesses, but […]
Over the past 15 years, more than 60% of asset growth among the top 30 biopharma companies came from acquisitions. Such inorganic growth is no […]
The European Commission has cleared AstraZeneca and Merck & Co’s Lynparza as an adjuvant or neoadjuvant treatment for breast cancer, extending its lead over would-be […]
Across the economy, several industries have seen a significant increase in staff turnover due to several factors including the COVID-19 pandemic, burnout, and increasing demand […]
The US FDA has approved a new biosimilar of Roche and Novartis’ blockbuster ophthalmology therapy Lucentis – Coherus BioSciences’ Cimerli – which its developer claims […]
Gilead Sciences’ investment in oncology has started to provide a solid return, with sales of cancer therapies breaching the $500 million threshold for the first […]
The Biden administration has confirmed its plans to start a booster vaccination campaign in the autumn, and placed a $1.74 billion order for 66 million […]
AstraZeneca chief executive Pascal Soriot said this morning that strong revenue increases in 2022 – fuelled by its COVID-19 antibody Evusheld and oncology drugs – […]
Oliver Stohlmann’s Corporate Survival Hacks series draws on his experiences of working in local, regional, and global life science communications to offer some little tips […]
With record-breaking revenues and profits accruing on the back of its COVID-19 products, Pfizer is planning a big spend on business development – but chief […]
Dupixent’s march towards becoming one of the world’s top-selling medicines continued at a healthy lick in the second quarter, allowing Sanofi to raise its full-year […]
Bristol-Myers Squibb’s new immune checkpoint inhibitor combination Opdualag has only been on the US market for a few weeks, but is already off to a […]
In its first set of financial figures since spinning off its consumer health division, GSK has reported a 19% increase in revenues, driven by burgeoning […]
Teva Pharmaceutical says it has reached an agreement in principle to settle thousands of lawsuits accusing it of fuelling the opioid crisis in the US […]
A just-published report on the UK’s life sciences sector “ought to ring alarm bells across government,” according to the Association of the British Pharmaceutical Industry […]
Drugmakers Pfizer and Flynn Pharma have been fined £70 million ($84 million) by the UK Competition and Markets Authority (CMA) for overcharging the NHS for […]
Long-serving Roche chief executive Severin Schwan is stepping down, to be replaced next March by Thomas Schinecker, currently head of diagnostics at the Swiss group. […]
With NHS England highlighting savings of £1.2 billion on medicines in three years coming from both deals on generics and new innovative treatments, Leela Barham […]
A Texas court has confirmed the $41.8 million damages awarded to Seagen in its patent dispute with Daiichi Sankyo over beast cancer drug Enhertu, but […]
Incyte’s Opzelura cream has become the first medical treatment approved to re-pigment the skin of people with vitiligo in the US, adding to its current […]
Novartis said this morning that it remains on course to make a decision on the future of its generics business Sandoz by the end of […]
Polpharma has become the first company to file for approval in the EU of a biosimilar version of Biogen’s blockbuster multiple sclerosis therapy Tysabri. The […]
AbbVie has submitted its oral CGRP inhibitor atogepant for prevention of both episodic and chronic migraine in the EU as it tries to catch up […]
GSK’s consumer health spinout Haleon started trading on the London Stock Exchange this morning, making its debut with a price of 330 pence and a […]
Teva has asked the Supreme Court to look at a judgment in a $235 million patent dispute with GSK that it claims could undermine the […]
Illumina’s attempt to prevent the European Commission from carrying out an antitrust review of its $8 billion takeover last year of cancer diagnosis firm Grail […]
Healthcare providers (HCPs) are facing a digital deluge and successive studies reveal that most messaging gets lost in the flood. The torrent of ill-directed communication […]
Health technology assessment (HTA) agency NICE has finalised its guidance on Amarin’s Vazkepa, clearing the path for GPs to start prescribing the drug in up […]
The European Commission’s failure to reveal text messages between president Ursula von der Leyen and Pfizer chief executive Albert Bourla on COVID-19 vaccine procurement has […]
Bayer’s venerable testosterone replacement product for men with hypogonadism – Nebido – is being sold to Grünenthal as the group continues a revamp of its […]
New York’s attorney general has accused Teva of lying to evade responsibility for its alleged role in fuelling the opioid epidemic in the state, and […]
La Jolla Pharmaceuticals dreams of building a lucrative business from its stable of drugs used in infectious diseases never really paid off, and the company […]
Swedish rare disease specialist Sobi is paying $55 million upfront to license rights to ADC Therapeutics’ lymphoma therapy Zynlonta – approved in the US last […]
A report by the Senate Finance Committee has concluded that AbbVie exploited a financial loophole introduced by former President Donald Trump in 2017 to avoid […]
The rumour that Merck & Co is preparing to make a sizeable offer to buy cancer specialist Seagen won’t go away. The latest report – […]
BioNTech has responded to a patent infringement lawsuit filed by fellow German biotech CureVac over its COVID-19 vaccine, saying it will “vigorously” defend itself. CureVac […]
A court in West Virginia has ruled that US drug distributors McKesson, AmerisourceBergen and Cardinal Health are not responsible for fuelling the opioid crisis that […]
I recently had the pleasure of attending the PING Conference 2022, which had the tagline of ‘The Golden Age for Life Sciences Innovation’. In part, […]
Trial organisers face intense competition to find and recruit eligible patients for atopic dermatitis studies. With more than 500 dermatology clinical trials currently underway, it […]
Sanofi has said it will make 30 of its most commonly prescribed medicines available at non-profit prices to 40 lower-income countries, as part of a […]
On the heels of approvals in the US, Europe and Japan, Bayer’s Kerendia for chronic kidney disease (CKD) associated with type 2 diabetes has been […]
Pfizer and BioNTech have signed a new $3.2 billion supply contract with the US government for COVID-19 vaccines, covering 105 million doses that may include […]
Already competing to bring the first vaccine against respiratory syncytial virus (RSV) to market, Pfizer and GSK are also fighting a patent infringement battle in […]
A Swiss newspaper has said Novartis’ previously announced restructuring programme could lead to 8,000 axed jobs, including up to 1,400 at its home base in […]
The revamp of French drugmaker Ipsen has continued with a takeover agreement for US counterpart Epizyme and its cancer therapy Tazverik, in a deal valued […]
Novartis’ two-drug regimen of Tafinlar and Mekinist has been approved by the FDA as the first therapy for solid tumours that have a BRAF V600E […]
US biotech Enanta Pharma has filed a lawsuit against Pfizer, claiming that its oral antiviral for COVID-19 Paxlovid infringes one of its patents and seeking […]
Novartis could lose years of patent protection in the US for its blockbuster multiple sclerosis therapy Gilenya, after a federal appeals verdict went against the […]
AbbVie has filed for approval of its oral CGRP inhibitor Qulipta for prevention of chronic migraine, seeking to leap ahead of its main rival in […]
AbbVie’s IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn’s disease after getting […]
Speculation that Merck & Co may be preparing a $30 billion takeover bid for Seagen – bolstering its oncology ambitions – has the biopharma community […]
AstraZeneca is rumoured to be considering a bid to take control of its longstanding partner Mereo BioPharma, according to a report in The Times, which […]
Manufacturing problems wreaked havoc with Mallinckrodt’s first attempt to secure FDA approval of its treatment candidate terlipressin for hepatorenal syndrome (HRS), but the drugmaker is […]
Four years after getting the first drug approved by the FDA to treat rare disease hereditary ATTR amyloidosis, Alnylam has got the go-ahead for a […]
Eli Lilly and Incyte’s Olumiant has secured the first FDA approval for a systemic drug to treat alopecia areata, an autoimmune condition causing patchy hair […]
Longstanding claims that one of the reasons for high drug prices in the US is the actions of pharmacy benefit management (PBM) companies – the […]
Each year across Europe, 3.7 million people are diagnosed with a form of cancer, resulting in 1.9 million deaths, making cancer the second largest cause […]
Eversana’s suite of commercialisation tools for pharma companies will soon have a new component – cognitive behavioural training tools designed to improve the performance of […]
GlaxoSmithKline is due to complete the split from its consumer health decision – now renamed Haleon – next month, with a listing for the new […]
To improve outcomes for cancer patients and take advantage of the ground-breaking scientific and technological progress made in oncology prevention, diagnosis, therapy and care over […]
The US Securities and Exchange Commission has sued a former AstraZeneca executive over alleged insider trading in connection with its 2019 deal to acquire rights […]
GlaxoSmithKline has agreed a $3.3 billion takeover of US biotech Affinivax, buying a pneumococcal vaccine candidate that is aiming to break into a market that […]
Roche and PTC Therapeutics’ Evrysdi for spinal muscular atrophy (SMA) has been approved by the FDA for younger children with the rare disease, extending its […]
Sanofi and Regeneron should hear from the FDA in the autumn whether it will approve their blockbuster immunology drug Dupixent as a therapy for rare […]
It has been eight years since Sanofi licensed rights to an over-the-counter version of erectile dysfunction (ED) drug Cialis from Eli Lilly, and the FDA […]
Capturing an audience is a critical task. Doing that in a wind tunnel of multi-channel white noise requires a special brand of cut-through. The standard […]
Servier is on course to get a return on its $1.8 billion takeover of Agios Pharma’s oncology business after getting a key FDA approval for […]
Eli Lilly’s home state of Indiana is set to benefit from a massive $2.1 billion investment by the pharma group, earmarked for two brand new […]
The move to online international meetings has left pharma companies with uncertainty around contact compliance. But new joint guidance, from the IFPMA, EFPIA, and PhRMA, […]
US pharma giant Pfizer has said it will sell some of its patented medicines at non-profit prices to 45 of the world’s poorest countries – […]
Industrial action at several GlaxoSmithKline manufacturing plants in the UK has been called off, after an improved pay deal was accepted by the Unite union. […]
Data is the powerhouse of the pharmaceutical sector. It powers drug discovery, clinical trials, and operational performance. But sizeable reservoirs of data remain unseen and […]
Sanofi and Regeneron have added another string to the bow of their immunology blockbuster Dupixent with an FDA approval in eosinophilic oesophagitis (EoE), which could […]
Former pharma executive Martin Shkreli, who became notorious for raising the price of a lifesaving AIDS drug around 5,000%, has been released early from his […]
Considerable scientific progress across neurological diseases and disorders was reported at the recent 74th American Academy of Neurology (AAN) Annual Meeting. What may be important […]
As the world and the UK continues its march out of the pandemic’s shadow, the pharmaceutical and life sciences sector has been squarely in the […]
Strategic coaching is bringing rewards across pharma as the industry adjusts to post-pandemic practices and challenges. Field forces are being realigned, business development re-focussed and […]
Arkansas has become the latest US state to issue a legal challenge to the big three insulin producers – Eli Lilly, Sanofi and Novo Nordisk […]
AbbVie’s Allergan subsidiary and Teva are reportedly considering making a $5 billion-plus offer to try to bring opioid liability lawsuits to a conclusion. According to […]
Not content with a $1.2 billion licensing deal for Biohaven Pharma’s oral migraine therapy rimegepant, Pfizer has just offered to buy the company outright – […]
Engaging, strategic, customer-centric communication is important in any industry, and no industry has been unaffected by the changing world of digital communication. But healthcare communicators […]
Seagen’s chief executive Clay Siegall has taken leave of absence pending an investigation into an alleged domestic violence incident at his home. Siegall denies the […]
A new “black cheque” company that claims to be the first in Europe devoted to biomanufacturing has been set up by a team of investors, […]
Sanofi has completed the spin-out of its pharma ingredients business EuroAPI, with shares in the new company rising more than 3% on its starting price […]
Novartis has shut down production of its radioligand therapies – one of its key growth areas – at facilities in Europe and the US after […]
Preparation and practice are potent forces in sales but they form a golden triangle when combined with feedback. Shaping performance with guidance elevates coaching to […]
Biogen has announced a major revamp of its business that will see chief executive Michel Vounatsos depart the company, and all commercial activities related to […]
Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, […]
AstraZeneca has revealed plans to set up a new strategic R&D hub in Cambridge, Massachusetts as it reported a massive increase in first-quarter revenues, driven […]
Oliver Stohlmann’s Corporate Survival Hacks series draws on his experiences of working in local, regional and global life science communications to offer some little tips […]
Orders for Merck & Co’s oral antiviral for COVID-19 helped to swell the drugmaker’s first quarter revenues by a massive 50%, although underlying growth was […]
Pfizer’s $1.2 billion licensing deal with Biohaven for rights to oral migraine drug rimegepant is approaching a payoff after the European Commission approved the drug. […]
GlaxoSmithKline has made a promising start to 2022 with a 32% rise in group sales, albeit measured against a downbeat first-quarter result in 2021. Vir […]
As the landscape of healthcare changes, so too must the way that we interpret and measure performance and success. This is particularly evident in marketing. […]
Making sure clinical trials are diverse and representative of the populations they’re studying isn’t just the right thing to do to promote inclusivity and equity; […]
Prescription drug use in the US soared last year, as might be expected during a pandemic, but is expected to fall back sharply in 2023, […]
Workers at a number of GlaxoSmithKline manufacturing plants in the UK have voted to take industrial action over what the Unite union has described as […]
The industry has long sought the insight and advice of revered, influential figures. Typically, these key opinion leaders (KOLs) are researchers, physicians, or other healthcare […]
In 2022, pharma is truly a global industry, and innovation can come from anywhere. But for small life sciences outside of the USA and Europe, […]
In a world of a million messages, should authenticity be the common thread tying all pharma communications and marketing activities together? Authentic, knowledgeable communications designed […]
US cost-effectiveness watchdog ICER has handed bluebird bio some good news ahead of its FDA advisory committee meeting for rare blood disorder gene therapy beti-cel […]
An appeals court in California has upheld a lower court ruling that ordered Johnson & Johnson to pay substantial penalties for deceptive marketing of its […]
Novartis has confirmed it is planning to reduce its headcount as part of a restructuring initiative announced last week, but has declined to put a […]
Training can be a bore; dull, predictable sessions shoe-horned into the diary when a meeting room is available or via a virtual session full of […]
The UK is poised to become the first country in the world to launch a new payment model for antibiotics that could reverse decades of […]
A US jury has decided that Daiichi Sankyo and AstraZeneca’s breast cancer drug Enhertu infringes a patent held by US biotech Seagen, awarding almost $42 […]
The US Centres for Medicare and Medicaid Services (CMS) has firmed up its draft decision to limit reimbursement of Biogen’s Alzheimer’s disease therapy Aduhelm to […]
Boehringer Ingelheim says it is planning to invest a hefty €25 billion ($27 billion) in its pipeline over the next five years, as it reinvests […]
Novartis chief executive Vas Narasimhan, already eyeing a possible divestment of generics business Sandoz, has now turned his attention to the rest of the company. […]
Leading tennis players train two to three hours a day to prepare for tournaments and have daily coaching input to make them game ready. It’s […]
German injectable medicines specialist Fresenius Kabi has made a pair of deals to kickstart its new strategic direction, including a majority stake in mAbxience that […]
Jazz Pharma has started construction of a manufacturing facility in the UK that will be used to manufacture cannabinoid drugs from its recently acquired GW […]
The US Senate will vote in the coming weeks on whether to introduce a $35 cap on the monthly cost of insulin to patients that […]
The world is re-balancing but the pharmaceutical industry’s engagement with HCPs has been tilted on its axis sending time-honoured engagement tactics into disarray. Face-to-face opportunities […]
Bavarian Nordic has licensed rights to its respiratory syncytial virus (RSV) vaccine in China and certain other Asian markets to Shanghai’s Nuance Pharma in a […]
AstraZeneca (AZ), GlaxoSmithKline (GSK), Sanofi, Allergan and Britannia Pharma have been reprimanded for running advertisements that breached the Association of British Pharmaceutical Industry (APBI) code […]
Alnylam claims it is owed a slice of the massive revenues booked by Pfizer and Moderna for their mRNA-based COVID-19 vaccines, because they are both […]
AstraZeneca has resolved a lingering liability following its takeover of Alexion with an agreement to pay $775 million to settle a patent dispute with Chugai […]
Viatris (formerly Mylan) has become the first drugmaker to win full FDA approval for a generic version of AstraZeneca’s top-selling respiratory drug Symbicort, although launch […]
How to make it in the new normal Part 1 of this article discussed the massive disruptions to medical events caused by the COVID-19 pandemic […]
The new normal is already here. Get used to it. The COVID-19 pandemic has radically disrupted traditional medical society conferences in a way that could […]
Japanese pharma Eisai has backed away from its 50:50 profit-sharing arrangement with Biogen for troubled Alzheimer’s therapy Aduhelm, handing over full responsibility to its US […]
Novartis may be planning to sell off its generics business Sandoz, but that hasn’t stopped it investing in the unit ahead of a decision on […]
In little over three decades, advances in biotechnology have noticeably disrupted the development landscape of small molecule drugs. Yet, despite the immense potential of the […]
Mallinckrodt’s liability problems in the US have been lightened slightly, after it agreed a $260 million deal to resolve allegations of Medicare rebate fraud and […]
Bristol-Myers Squibb’s blood cancer blockbuster Revlimid is finally facing generic competition in the US, which will eat into revenues from a drug that made a […]
As bluebird bio struggles to get its gene therapies over the finishing line, the company says its financial position raises “substantial doubt” about its ability […]
The pharmaceutical industry is still picking its way through the debris of the pandemic but the gloom can be illuminated by the power of coaching […]
Novo Nordisk’s rollout of obesity therapy Wegovy has been beset by production problems, but the company says these are being resolved and it now anticipates […]
Purdue Pharma and its controlling Sackler family have reach a new settlement to resolve lawsuits over their involvement in the opioid epidemic, raising the payout […]
Non-profit drugmaker Civica Rx has said it will launch biosimilars of three big-selling insulin products in the US by 2024 to help diabetic patients struggling […]
Hundreds of business leaders in the life sciences sector have added their names to an open letter that says they will cease all business dealings […]
India’s Biocon has expanded its pipeline of biosimilars with a $3.3 billion deal to acquire a portfolio of drugs from Viatris, the parent of its […]
Johnson & Johnson and the ‘big three’ US pharm wholesalers say they are close to finalising a $26 billion settlement that could allow them to […]
GlaxoSmithKline’s consumer health business will be named Haleon following its planned spinoff and listing on the London Stock Exchange later this year, according to the […]
Oliver Stohlmann’s Corporate Survival Hacks series draws on his experiences of working in local, regional and global life science communications to offer some little tips […]
Bayer now says it expects to make €3 billion in sales for its prostate cancer treatment Nubeqa, up from an earlier estimate of €1 billion, […]
Collegium Pharma has expanded its pain franchise though a deal to acquire BioDelivery Sciences International (BDSI), which has three FDA-approved drugs and a new migraine […]
Ipsen has started exclusive negotiations that could see its global consumer health business sold to fellow French pharma company Mayoly Spindler later this year. If […]
GlaxoSmithKline’s COVID-19 products – antibody drug Xevudy and a vaccine adjuvant – helped drive a 5% increase in 2021 revenues to £34 billion ($46 billion), […]
Pfizer reckons it will make a whopping $22 billion in sales of its oral COVID-19 antiviral Paxlovid in 2022, with another $32 billion from its […]
India’s Dr Reddy’s Laboratories has joined the growing list of pharma companies that are looking to tap into the market for medical cannabis, buying German […]
Roche has warned that revenue growth will come under pressure in the coming year as sales of its COVID-19 testing kits start to slow, exposing […]
Oliver Stohlmann’s Corporate Survival Hacks series draws on his experiences of working in local, regional and global life science communications to offer some little tips […]
The UK Competition and Markets Authority has ruled that several drugmakers worked together to raise the NHS price of widely-used nausea drug prochlorperazine, fining them […]
Novartis chief executive Vas Narasimhan has downplayed any chances of swift decision on the future of its generics business Sandoz, saying that a decision on […]
A patent dispute between ViiV Healthcare and Gilead Sciences has been resolved, with Gilead agreeing to pay a $1.25 billion settlement as well as royalties […]
Creating personalised, compliant content is becoming increasingly important for life science companies as HCPs demand more from their digital content. Pharma companies created 3.5 times […]
The failure of the European Commission to locate text messages between its president Ursula von der Leyen and Pfizer chief executive Albert Bourla on procurement […]
Eli Lilly has said it is seeking permission to build a new biopharmaceutical manufacturing facility in Ireland that will be used to produce active ingredients […]
Recent rumours that Biogen was about to acquired by Samsung proved unfounded, but it turns out a deal has been in preparation. The South Korean […]
Biogen and Eisai have increased the earning potential of their Alzheimer’s drug Aduhelm by expanding the post-marketing trial of the drug required by the FDA […]
Johnson & Johnson has said the impending spin-off of its consumer health division won’t stop it from “forging ahead” with M&A deals to expand its […]
Mark Cuban, billionaire owner of the Dallas Mavericks basketball team, just got involved in the online pharmacy business, promising to “shield consumers from inflated drug […]
The FDA has limited the use of COVID-19 antibody therapies developed by Eli Lilly and Regeneron, on the back of data suggesting they have are […]
Oskar Möbert, Vice President OpenData Europe at Veeva Systems, tells us how they are reimagining customer reference data to boost pharma rep productivity, enable more […]
The FDA has extended the emergency use authorisation for Gilead Sciences’ antiviral Veklury to include non-hospitalised patients with COVID-19, extending the uses of the drug. […]
Companies seek efficiency and speed to market during the content creation process, review and approval cycles, and thus the collective time for content to be […]
The digital revolution generated by the pandemic fractured lines of connection and severed the life-blood of being able to meet with clinicians for sales teams […]
In 2020, over half of total spending on brand medicines went to the supply chain, middlemen and other stakeholders, overtaking the amount going to drug […]
Biogen’s difficult launch of controversial Alzheimer’s therapy Aduhelm has been made even harder by a proposal by Medicare to cover the drug only for certain […]
The pandemic has given us a surge of opportunities to take fresh looks at how we live, work and play with huge changes of pace […]
Regeneron has enlisted the aid of Ultragenyx to add momentum to the rollout of its recently-approved Evkeeza outside the US, which was approved for an […]
The latest pharma company to make a move for an mRNA specialist is Germany’s Merck KGaA, which has offered a $780 million cash buyout to […]
Novartis has blocked an attempt by Chinese drugmaker HEC Pharma to launch a generic version of its big-selling multiple sclerosis drug Gilenya in the US […]
The jury in a new York trial has found that Teva Pharmaceuticals played a role in fuelling the opioid crisis in the US, and should […]
Sanofi and Regeneron have another challenger to their big-selling drug Dupixent for atopic dermatitis, now that the FDA has approved Leo Pharma’s rival antibody tralokinumab. […]
COVID-19 has changed everything – at least that’s David Hunt’s plan for pharmaceutical marketing. The former CEO of Havas Lynx recently launched a new agency […]
At its second attempt, Novartis has won FDA approval for its cholesterol lowering drug inclisiran, which can reduce levels with just two injections a year. […]
Patient centricity and patient engagement have been hot topics in pharma for some time – but buzz words do not always translate into concrete action. […]
Creating certainty in a landscape still convulsed by the pandemic is a lofty ambition, but pharma companies can use the disruption to develop positive internal […]
Amgen has won FDA approval for a stronger label for its oral plaque psoriasis therapy Otezla, as it prepares for competition from Bristol-Myers Squibb’s much-touted […]
In early 2020, health officials were cautious about forecasting a COVID-19 vaccine timeline to the public, as vaccine discovery was a historically laborious process that […]
Industry’s free pass to its target audience has been shredded by the pandemic leaving the sales force compass struggling to find effective routes. It has […]
Biogen has cut the list price of its Alzheimer’s disease therapy in half from $56,000 to $28,200 a year, before the outcome of an ongoing […]
A judge in the US has rejected the bankruptcy plan proposed by Purdue Pharma to settle legal action over its role in the opioid crisis, […]
Biogen and partner Eisai have said they will provide details next March for the confirmatory trial that will be needed to upgrade the drug’s accelerated […]
Bristol-Myers Squibb’s rheumatoid arthritis drug Orencia has been approved by the FDA to prevent graft versus host disease (GvHD), a serious complication of haematopoietic stem […]
Australian biotech group CSL has agreed a deal to acquire Swiss drugmaker Vifor Pharma in an all-cash deal that expands its speciality medicines business. If […]
AbbVie has ended speculation about what it will charge for its newly-approved Vuity therapy for presbyopia, a sight condition characterised by difficulty in focusing on […]
A pharma company formerly led by ‘pharma bro’ Martin Shkreli has settled a long-running lawsuit with the US federal government over massive price increases for […]
Personal relationships have been the dominant force in sales for generations but the pandemic has ripped up this conveyer belt of convenience. More than 60% […]
Since the onset of the Covid-19 pandemic, life science companies have acted quickly to address the evolving digital needs of healthcare professionals, with mixed success […]
An $8 billion attempt by two private equity companies to acquire Swedish rare disease specialist Sobi and take it back into private ownership has collapsed, […]
The seismic shift away from face-to-face meetings caused by the pandemic has given the pharmaceutical industry a fundamental challenge around engaging with clinical staff. Sales […]
The UK government has placed a 114 million-dose order with Pfizer/BioNTech and Moderna – sufficient to provide two doses to every person in Britain – in […]
Oliver Stohlmann’s Corporate Survival Hacks series draws on his experiences of working in local, regional and global life science communications to offer some little tips […]
Janssen’s Mark Larsen, VP & Head of HR at Janssen EMEA, looks at what COVID-19 has taught us about good leadership and how we develop […]
Novo Nordisk has said that the introduction of value-based procurement (VBP) for insulin products by the Chinese government will have an impact on its revenues […]
Healthcare professional (HCP) engagement experienced significant shifts during the acute phase of the pandemic, as COVID-19 forced a rethink of traditional pharmaceutical sales and marketing […]
Just a few weeks after Novartis revealed it was considering a sale of its generics business Sandoz, there are reports that a potential buyer has […]
Already making big profits from its COVID-19 vaccine, Pfizer looks set to bolt on another big revenue stream with its oral antiviral drug Paxlovid after […]
The US has made a sizeable order for GlaxoSmithKline and Vir Biotechnology’s antibody-based COVID-19 treatment sotrovimab said to be worth approximately $1 billion. The deal […]
With drug pricing controls back on the legislative table in the US, the influential Institute for Clinical and Economic Review (ICER) has published its third […]
After decades of a diversified healthcare business model, Johnson & Johnson has announced it plans to split off its consumer health division from its pharma […]
AstraZeneca has said it plans to start making a small profit from sales of its COVID-19 vaccine Vaxzevria, which brought in just over $1 billion […]
Heather Barnes, external innovation lead EMEA at Johnson and Johnson Consumer Health, is a scientist who is truly passionate about consumer health. With her background […]
Shares in France’s Valneva leaped after it got an EU order to supply 60 million doses of its COVID-19 vaccine VLA2001 over the next two […]
Pfizer has bolstered its central nervous system (CNS) drugs portfolio with a $1.2 billion deal to claim rights outside the US to Biohaven’s Nurtec ODT, […]
The US federal government has ordered another 1.4 million doses of Merck & Co and Ridgeback Biotherapeutics’ oral antiviral molnupiravir for COVID-19, adding to an […]
COVID-19 has been a catalyst for a huge amount of change across the pharmaceutical industry, acting as an accelerant for progress in its use of […]
COVID has forced the pharma industry to step up and take a more innovative approach to the channels and content it uses to reach and […]
Switzerland’s Social Democratic Party has argued that the government should step in and acquire Novartis’ generics unit Sandoz if the company decides to sell it, […]
Under fire for abandoning a plan to allow Medicare to negotiate drug pricing, Democrats in the Senate have reached an agreement that could see the […]
After more than 20 years, Novartis has finally decided to sell its substantial share in fellow Swiss pharma group Roche for $20.7 billion, a decent […]
Rocketing sales of COVID-19 vaccine Comirnaty have allowed Pfizer to raise its full-year forecasts for the shot once again to a whopping $36 billion, more […]
President Joe Biden has jettisoned a raft of policy proposals aimed at curbing the price of prescription medicines as part of the US administration’s $1.75 […]
Oliver Stohlmann’s Corporate Survival Hacks series draws on his experiences of working in local, regional and global life science communications to offer some little tips […]
COVID-19 demonstrated the importance of robust supply chains and the dangers of an over reliance on overseas manufacturing. But can the Pharmaceutical Strategy for Europe […]
Novartis revealed today that it may consider divesting its generic medicines subsidiary Sandoz – amongst other options – which would further narrow its focus to […]
Activist investors are pushing back against Merck & Co’s recent $11.5 billion deal to acquire Acceleron Pharma, arguing that its $180-per-share offer seriously undervalues the […]
Stakeholder expectations are high and, with all eyes on healthcare at the moment, it is essential for companies to go beyond generic commitments, says Rosanna […]
The company’s senior vice president for major markets (Europe, Canada and Japan) talks about the continued evolution of pharma’s approach to communications and commercialisation. The […]
Analysts were predicting sales of Biogen’s recently approved Alzheimer’s therapy Aduhelm may start to gather a little momentum in the third quarter, but the drug […]
High demand for COVID-19 diagnostics driven by the delta variant has led to rocketing sales at Roche’s diagnostics division, allowing the company to raise its […]
Johnson & Johnson has been offering its COVID-19 vaccine for sale on a no-profit basis since it became available, but is thinking about a possible […]
Patient centricity has become a key aspiration for the pharma industry over the last several years, but getting entire organisations to think and behave in […]
Biosimilar competition to AbbVie’s big-selling Humira drug in the US has just been ratcheted up by the FDA approval of Boehringer Ingelheim’s Cyltezo – which […]
SMi Group’s 13th Annual Conference: RNA Therapeutics 2022 9th – 10th February 2022 London, UK www.therapeutics-rna.com/pharmaphorum Sponsored by: BIA Separations & eTheRNA Immunotherapies Bolstering the […]
Companies looking to replicate a drug’s EU market success in the US will face significant hurdles unless they are fully aware of the ever-changing national […]
Episode 42 of the pharmaphorum podcast heard from Catherine Owen, who’s senior vice president of major markets at Bristol Myers Squibb, about the future of […]
Digital Health veteran Eugene Borukhovich has joined Healthware Group as senior advisor to its Media and Community business unit, which aims to foster dialogue and […]
Pharma companies are embracing patient centricity in drug development more than ever before. Over the last decade, leaders in the industry have championed patient engagement, […]
IQVIA’s Sarah Rickwood and Markus Gores look at how to deliver consistent launch performance in an increasingly complex world. Launching a new product is an […]
The traditional sales channel for the pharmaceutical industry has centered on face-to-face interaction with its core target audience – prescribing physicians. What happens when suddenly […]
Roche’s Actemra has been in high demand since its value in treating severe COVID-19 was established, leading to shortages. Now, Sanofi’s rival therapy Kevzara has […]
Supernus has boosted its position in central nervous system therapies with a $400 million deal to acquire Adamas Pharma that will add two approved Parkinson’s […]
Pharmaceutical companies are traditionally more conservative with their approach to and incorporation of new technologies; however, prior to COVID, the industry had begun moving toward […]
The pharma industry has been talking about being patient-centric for years, but often that rhetoric hasn’t been accompanied by real change in the way product […]
So much effort goes into ensuring the successful launch of a new pharmaceutical product or indication, but it’s only once that has been achieved that […]
Since 2019, pharmaceutical companies have been speeding to integrate digital channels and processes into their marketing efforts and patient outreach, to prepare for the wave […]
M3’s Tim Russell and Maxim Polyakov, together with Digital Futureway’s Heather Hancock, discuss new research on how doctor engagement has been altered by COVID-19. COVID-19 […]
The COVID-19 pandemic kickstarted a period of profound change in how the pharmaceutical industry approaches both communications and commercialisation. In some cases it was an […]
Shares in DNA sequencing specialist Oxford Nanopore rocketed after the company made its debut on the London Stock Exchange yesterday, rising nearly 50% to propel […]
After days of speculation, Merck & Co confirmed today that it has agreed to acquire Acceleron Pharma $1.5 billion, setting up what could be one […]
In this instalment of EPG Health’s HCP engagement series, Georga Cottle discusses how case-based learning connects medical theory to medical practice. Medical education doesn’t stand […]
Oliver Stohlmann’s Corporate Survival Hacks series draws on his experiences of working in local, regional and global life science communications to offer some little tips […]
US biopharma company Acceleron is the next company heading for a takeover by a big pharma group – according to a Bloomberg report citing people […]
Activist hedge fund Bluebell Capital Partners has joined Elliott Investment in taking a stake in GlaxoSmithKline and pushing for change at the drugmaker. In a […]
Copyright © 2024 | WordPress Theme by MH Themes